Indrayani Biotech Limited has announced its approval for a Rights Issue of up to 3,25,25,897 partly paid-up Equity Shares at an issue price of ₹15 per share. The issue aims to raise approximately ₹4878.88 lakh to fund working capital requirements, repay outstanding loans, and for general corporate purposes. The rights are being offered in the ratio of 5 shares for every 7 fully paid-up shares held as of the record date, April 28, 2026.
Rights Issue Details Approved
Indrayani Biotech Limited announced on September 9, 2026, that its Rights Issue Committee has approved the Letter of Offer for its proposed Rights Issue. The company plans to issue up to 3,25,25,897 partly paid-up Equity Shares of face value ₹10 each at an issue price of ₹15 per share (including a premium of ₹5 per share).
The aggregate amount expected to be raised through this issue, assuming full subscription, is approximately ₹4878.88 lakh.
Purpose of the Issue
The funds raised from this Rights Issue are intended to be utilized for the following primary purposes:
- To partially finance the company’s working capital requirements.
- To repay an outstanding loan of ₹548 lakh extended by the promoter, up to ₹500 lakh, by allotting equity shares to the promoter’s entitlement.
- To repay an outstanding unsecured advance of ₹1,275 lakh received from Bougainvillea Investments Private Limited by allotting equity shares at the Rights Issue price.
- To meet general corporate purposes.
- To cover the expenses associated with the Issue.
The proposed issue proceeds are earmarked with ₹2,064.64 lakh for working capital, ₹500.00 lakh for setting off the promoter’s loan, ₹1,275.00 lakh for setting off the advance from Bougainvillea Investments Private Limited, and ₹964.24 lakh for general corporate purposes.
Rights Entitlement Ratio
The Rights Issue is being offered on a rights basis to the eligible equity shareholders in the ratio of 5 (Five) partly paid-up Rights Equity Shares for every 7 (Seven) fully paid-up Equity Shares of ₹10 each held by them as on the record date, which is April 28, 2026.
Issue Schedule
The Issue opens on September 15, 2026, and closes on October 14, 2026. The last date for market renunciation of rights entitlements is October 08, 2026.
Listing and Trading
The company has received in-principle approval from BSE for the listing of the Equity Shares to be allotted pursuant to this Issue. The Equity Shares will be listed on the BSE Limited.
Source: BSE
